This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://localhost/temp/predkladatel/
n8http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n13http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11150%2F04%3A00004510%21RIV08-MSM-11150___/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n16http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11150%2F04%3A00004510%21RIV08-MSM-11150___
rdf:type
n13:Vysledek skos:Concept
dcterms:description
Tato práce shrnuje výsledky studie provedené za účelem ověření účinnosti léčby epoetinem alfa u pacientů s různými hematologickými onemocněními a současně zhodnocení dopadu této léčby na jejich kvalitu života. Účinnost léčby byla hodnocena zvýšením krevních hladin hemoglobinu a spotřebou substrátů erytrocyty potřebných ke kontrole anemického syndromu. Studie byla provedena na 134 pacientech s různými lymfoproliferativními onemocněními z nichž 127 bylo monitorováno alespoň 3 měsíce v průběhu terapie epoetinem alfa. Příznivý účinek léčby byl viditelný u pacientů s mnohočetným myelomem (85,7%), Waldenstrőmovou makroglobulinémií (80%) a chronickou lymfatickou leukémií (76,7%). Naopak, nejnižší účinnost byla u pacientů s myelodysplastickým syndromem. The communication is summarizing results of study aimed to ascertain the efficacy of treatment with epoetin alpha in patients with different hematological disorders and, at the same time to evaluate the impact of this treatment on quality of their lives. Treatment efficacy in separate patients of the monitored population has been evaluated not only according to hemoglobin level increase, but also according to its effect on erythrocyte products consumption needed to control anemic syndrome. Overall 134 patients with different lymphoproliferative disorders were included in the evaluation. Full-extended monitoring, i.e. at least 3-month treatment with epoetin alpha, was passed by 127 (94.8%) patients. Favorable effect of epoetin alpha administration was most often reported in patients with multiple myeloma (85.7%), Waldenstrom's macroglobulinemia (80%) and chronic lymphatic leukemia (76.7%). Conversely the lowest efficacy was reported in the group of patients with myelodysplastic syndrome. The communication is summarizing results of study aimed to ascertain the efficacy of treatment with epoetin alpha in patients with different hematological disorders and, at the same time to evaluate the impact of this treatment on quality of their lives. Treatment efficacy in separate patients of the monitored population has been evaluated not only according to hemoglobin level increase, but also according to its effect on erythrocyte products consumption needed to control anemic syndrome. Overall 134 patients with different lymphoproliferative disorders were included in the evaluation. Full-extended monitoring, i.e. at least 3-month treatment with epoetin alpha, was passed by 127 (94.8%) patients. Favorable effect of epoetin alpha administration was most often reported in patients with multiple myeloma (85.7%), Waldenstrom's macroglobulinemia (80%) and chronic lymphatic leukemia (76.7%). Conversely the lowest efficacy was reported in the group of patients with myelodysplastic syndrome.
dcterms:title
Treatment of associated anemia in different hematological disorders with epoetin alpha Léčba přidružené anémie pomocí epoetinu alfa u různých hematologických onemocnění Treatment of associated anemia in different hematological disorders with epoetin alpha
skos:prefLabel
Léčba přidružené anémie pomocí epoetinu alfa u různých hematologických onemocnění Treatment of associated anemia in different hematological disorders with epoetin alpha Treatment of associated anemia in different hematological disorders with epoetin alpha
skos:notation
RIV/00216208:11150/04:00004510!RIV08-MSM-11150___
n3:strany
379;384
n3:aktivita
n10:S
n3:aktivity
S
n3:cisloPeriodika
5
n3:dodaniDat
n16:2008
n3:domaciTvurceVysledku
n8:5303621
n3:druhVysledku
n6:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
590746
n3:idVysledku
RIV/00216208:11150/04:00004510
n3:jazykVysledku
n12:eng
n3:klicovaSlova
Treatment; associated; anemia; different; hematological; disorders; epoetin; alpha
n3:klicoveSlovo
n4:disorders n4:associated n4:epoetin n4:anemia n4:different n4:alpha n4:Treatment n4:hematological
n3:kodStatuVydavatele
SK - Slovenská republika
n3:kontrolniKodProRIV
[12679AC557C4]
n3:nazevZdroje
Neoplasma
n3:obor
n9:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
2
n3:rokUplatneniVysledku
n16:2004
n3:svazekPeriodika
51
n3:tvurceVysledku
Maisnar, Vladimír
s:issn
0028-2685
s:numberOfPages
6
n11:organizacniJednotka
11150